24/7 Market News Snapshot 24 September, 2025 – Immuneering Corporation Class A Common Stock (NASDAQ:IMRX)

September 24, 2025

DENVER, Colo., 24 September, 2025 (www.247marketnews.com) – (NASDAQ:IMRX) are discussed in this article.
Immuneering Corporation has recently achieved remarkable milestones, reflecting both a surge in market performance and promising clinical advancements in oncology. The company’s stock witnessed a significant upswing, opening at $8.64 and soaring to $14.46, representing an extraordinary increase of over 68% in a single trading session. This substantial rise followed the previous day’s close at $8.59, with trading volume reaching 3.62 million shares, indicating robust investor excitement and confidence in Immuneering’s growth trajectory.

Concurrently, Immuneering has announced groundbreaking findings from its Phase 2a trial of atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel (mGnP) for the first-line treatment of pancreatic cancer. The study, which enrolled 34 patients, demonstrated an impressive overall survival (OS) rate of 86% during a median follow-up period of nine months, significantly higher than the standard care benchmark of approximately 47%. Moreover, the nine-month progression-free survival (PFS) rate was reported at 53%, markedly exceeding the standard of care rate of about 29%.

Ben Zeskind, Ph.D., CEO of Immuneering, expressed enthusiasm over the results, stating, “Overall survival is the gold standard in oncology, and we are thrilled to report that our extraordinary 94% OS at six months was sustained, showing an even larger gap as time progresses.” He emphasized the transformative potential of the treatment for first-line pancreatic cancer patients, attributing its effectiveness to Immuneering’s innovative Deep Cyclic Inhibitors (DCIs), which aim to address the resistance often faced in cancer therapies.

Immuneering is poised for further developments, anticipating regulatory feedback on pivotal trial plans by Q4 2025, with the initiation of a Phase 3 trial planned by the end of 2025. As the company steadfastly commits to bringing forth new therapeutic options, it continues to make significant strides in enhancing patient outcomes in the challenging landscape of cancer treatment.

Related news for (IMRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.